U.S. Prostate-Specific Antigen Test Market Size & Share 2026-2035

U.S. Prostate-Specific Antigen Test Market Size

The U.S. prostate-specific antigen test market was valued at USD 1.5 billion in 2025 and is projected to increase from USD 1.6 billion in 2026 to USD 2.7 billion by 2035, at a 6.1% CAGR.

Underlying demand extends beyond first-line screening. The American Cancer Society estimated 313,780 new U.S. prostate cancer cases in 2025, while NCI projected 333,830 new cases and 36,320 deaths for 2026. ^{[1]American Cancer Society, Prostate Cancer Statistics, 2025, CA: A Cancer Journal for Clinicians, 2025, doi.org [2]National Cancer Institute, Cancer Trends Progress Report: PSA Testing Rate by Race/Ethnicity, 2005-2023, progressreport.cancer.gov} An estimated 3.7 million men were living with prostate cancer in the United States in 2023, creating a large base for serial PSA measurement after treatment and during active surveillance.

Screening gaps and disease disparities add an important volume dimension. PSA testing among men aged 55-69 was 38.0% in 2023, and uptake among non-Hispanic Black men was 33.5%, compared with 41.8% among non-Hispanic White men. This gap is clinically material because Black men experience substantially higher prostate cancer incidence and mortality than White men. . Rising incidence, a growing survivor population, and risk-based testing pathways are therefore expanding demand for both routine PSA assays and higher-value reflex diagnostics.

The clinical foundation remains durable. Incidence has risen by 2.7% annually during 2014-2023, while the population living with prostate cancer requires monitoring long after diagnosis. Standard total PSA remains the entry point to that pathway, but abnormal results increasingly trigger free PSA, multi-kallikrein, structural-variant, imaging, or genomic testing. Revenue growth is consequently less dependent on a single screening guideline than on the expanding number of clinical decisions that follow a PSA result.

Key Drivers

Increasing prostate cancer incidence and survivorship

Prostate cancer incidence is increasing after a prolonged earlier decline, with NCI reporting a 2.7% annual increase from 2014 to 2023. The effect on testing demand is amplified by survivorship: localized disease has a 5-year relative survival rate of 98.2%, leaving a large cohort in follow-up care where PSA trajectories are used to identify biochemical recurrence and assess active surveillance.

The clinical impact is especially pronounced in higher-risk populations. Black men have markedly higher incidence and mortality, but lower reported screening participation than White men. . Health systems that improve risk-based outreach in these communities can increase access to first-line PSA testing while also identifying more patients who require confirmatory diagnostics.

Technological advancement in assay platforms

Automation remains central to the high-volume segment. Siemens' Atellica IM Total PSA II received FDA premarket approval in December 2025 and is standardized against the WHO 17/100 reference material. ^{[3]U.S. Food and Drug Administration, Premarket Approval P240021: Atellica IM Total PSA II, December 2025, accessdata.fda.gov} Siemens offers PSA, free PSA, and complexed PSA across Atellica IM, ADVIA Centaur, Dimension Vista, and IMMULITE platforms, allowing laboratories to align assay deployment with throughput and site requirements. ^{[4]Siemens Healthineers, Prostate Cancer Laboratory Diagnostics, siemens-healthineers.com} Roche's Elecsys total PSA assay similarly supports testing on its cobas e immunoassay systems.

Innovation is increasingly focused on specificity rather than concentration alone. Beckman Coulter's Prostate Health Index combines total PSA, free PSA, and p2PSA to support prostate cancer risk assessment in the diagnostic gray zone. Cleveland Diagnostics' IsoPSA received FDA approval in December 2025 as an aid to biopsy decision-making for men aged 50 years and older with elevated PSA, using structural variants of PSA rather than total concentration alone. ^{[5]U.S. Food and Drug Administration, Premarket Approval P200048: IsoPSA Assay, accessdata.fda.gov [6]Cleveland Diagnostics, Inc., FDA Approves IsoPSA Novel Blood-Based Prostate Cancer Test, December 1, 2025, businesswire.com} These tests create a commercial rationale for laboratories to offer differentiated reflex pathways rather than relying exclusively on standardized total PSA testing.

Risk-stratified screening and early diagnostic pathways

The USPSTF recommends individualized decision-making for PSA-based screening in men aged 55-69 and recommends against routine screening in men aged 70 years and older. ^{[7]U.S. Preventive Services Task Force, Final Recommendation Statement: Prostate Cancer Screening, uspreventiveservicestaskforce.org} Medicare separately covers annual PSA screening for eligible male beneficiaries aged 50 years and older under National Coverage Determination 210.1. ^{[8]Centers for Medicare & Medicaid Services, National Coverage Determination 210.1: Prostate Cancer Screening Tests, cms.gov} The coexistence of individualized clinical guidance and a defined payment pathway supports continued testing while shifting the ordering decision toward patient risk, age, life expectancy, and preferences.

A PSA-first pathway also supports downstream assessment when a result is elevated. FDA-approved 4Kscore testing incorporates four kallikrein biomarkers and clinical variables to estimate the probability of high-grade prostate cancer before biopsy,. In a meta-analysis, the test demonstrated pooled discrimination for high-grade disease with an area under the curve exceeding 0.80. Such risk refinement can make PSA testing more clinically actionable by separating patients who need further workup from those who may avoid an immediate invasive procedure.

Key Restraints

High cost and variable coverage of advanced assays

Routine PSA testing benefits from established laboratory workflows and a defined Medicare screening benefit. Advanced protein, RNA, and tissue-based assays face a more fragmented reimbursement environment, often requiring evidence of clinical indication and adherence to payer-specific criteria. Coverage policies for prostate cancer biomarkers identify eligible uses for tests such as 4Kscore, ExoDx, SelectMDx, and ConfirmMDx, but the requirements vary by payer and test category.

This fragmentation affects adoption economics. A laboratory or urology practice may be able to justify routine PSA testing at scale, yet lack sufficient reimbursed demand to bring specialized biomarker capabilities in house. Consequently, advanced assays are frequently routed through specialty or national reference laboratories, preserving access but adding ordering, authorization, and specimen-routing friction.

Screening guideline variability and overdiagnosis concerns

PSA screening remains clinically contested because its benefits depend on patient selection, follow-up quality, and the avoidance of unnecessary biopsy or treatment. The USPSTF's Grade C recommendation for ages 55-69 formalizes shared decision-making rather than population-wide routine screening, while the Grade D recommendation for men aged 70 years and older limits standardization across primary-care settings.

Different professional recommendations on starting age, screening interval, and follow-up thresholds can further complicate protocol design for health systems and physician practices. Concerns about overdiagnosis are not merely clinical: they influence payer policy, physician willingness to order screening, and patient acceptance. The market therefore depends on tests and workflows that improve the information value of an elevated PSA result rather than simply increasing screening frequency.

Guideline fragmentation is likely to persist because it reflects genuine trade-offs around overdiagnosis, life expectancy, and patient preference. Its commercial effect is softening, however, as shared decision-making makes PSA an entry point into risk-stratified care. Suppliers that pair broad PSA access with clear reflex-testing criteria are better positioned than those that depend on undifferentiated screening volume alone.

U.S. Prostate-Specific Antigen Test Market Segment Analysis

By Product

Preliminary tests accounted for 73.4% of market revenue in 2025, or approximately USD 1,101 million, and are projected to reach USD 2.0 billion by 2035 at a CAGR of 5.7%. Their scale reflects the central role of total PSA, free PSA, and related assays in screening, surveillance, and initial assessment of elevated PSA.

Total PSA is the highest-volume component of the preliminary category because it is used across screening, post-treatment monitoring, and active surveillance. The assay's economics are shaped by automation, broad installed-base availability, and increasing comparability across platforms through WHO 17/100 standardization. . Standardization improves continuity when patients are tested across sites, but it also narrows the scope for assay manufacturers to command a substantial premium on basic total PSA measurement.

Free PSA is most relevant after an elevated total PSA result, particularly in the range where benign disease and malignancy are difficult to distinguish. Roche and Siemens offer free PSA assays on established laboratory platforms, enabling laboratories to integrate reflex measurement with total PSA testing. . Its value lies less in standalone test volume than in improving the clinical interpretation of a total PSA result and supporting more selective referral decisions.

Other preliminary tests include algorithmic assays such as PHI, 4Kscore, and IsoPSA. PHI combines total PSA, free PSA, and p2PSA, while 4Kscore uses four kallikrein biomarkers and clinical factors to estimate the likelihood of high-grade disease,. IsoPSA applies structural analysis of PSA protein variants to support biopsy decisions. . These assays address the same clinical bottleneck, but their differentiated analytical approaches create room for premium pricing and test selection based on laboratory access, clinical preference, and payer coverage.

Confirmatory tests generated USD 408.4 million in 2025. Although lower in volume than preliminary tests, the category captures higher-value decisions after an abnormal PSA result, including lesion localization, biopsy guidance, tissue characterization, and genomic risk assessment.

Multiparametric MRI and MRI/ultrasound fusion systems are increasingly embedded in the diagnostic workup of patients with elevated PSA. GE HealthCare's prostate MRI workflow tools support automated prostate segmentation, PSA density calculation, and lesion localization. Philips' DynaCAD Prostate and UroNav platforms connect prostate MRI analysis with fusion-biopsy workflows,. Imaging capacity and radiologist availability remain practical constraints, but AI-enabled workflow tools may improve throughput where specialist infrastructure is already present.

Tissue-based genomic classifiers provide high-value information after biopsy or surgery. Veracyte's Decipher Prostate test was identified by Veracyte as the only gene-expression test in the NCCN Prostate Cancer Guidelines' 2025 Advanced Tools table with Level 1B evidence. Myriad's Prolaris combines gene-expression information with clinical risk assessment to support decisions around active surveillance and treatment. These tests gain value when the clinical question is no longer whether cancer is present, but whether a patient's disease biology warrants surveillance, local treatment, or intensified management.

Other confirmatory tests include urine-based molecular assays and emerging liquid-biopsy approaches. MDxHealth's acquisition of Exosome Diagnostics added the ExoDx Prostate test and a related CLIA-certified laboratory to its prostate cancer diagnostics portfolio. The transaction strengthened MDxHealth's ability to offer non-invasive risk stratification alongside SelectMDx, ConfirmMDx, and Genomic Prostate Score services. Such portfolio consolidation can reduce the number of laboratory relationships a physician must manage, although payer acceptance remains decisive for routine adoption.

By Application

Prostate cancer screening generated USD 908.7 million in 2025. Medicare coverage for annual PSA screening among eligible men aged 50 years and older provides an important baseline for the application. Screening growth is nevertheless moderated by guideline-directed shared decision-making and uneven uptake among risk groups. .

Prostate cancer monitoring represented 40.8% of 2025 revenue, or approximately USD 612 million. Monitoring has a structurally different utilization pattern from screening: patients may receive repeated PSA measurements following treatment, during active surveillance, or while evaluating biochemical recurrence. The expanding prevalent population and high survival rate make this application less sensitive to changes in first-time screening participation.

By End Use

Independent commercial reference laboratories held 35.9% of market revenue in 2025, or approximately USD 538.5 million. National reference laboratories process high-volume routine PSA testing efficiently and provide a distribution channel for specialty assays that smaller provider sites may not perform internally. Quest Diagnostics' national laboratory infrastructure, for example, supports both routine clinical testing and access to new diagnostic offerings.

Hospital-based laboratories accounted for 30.7% of revenue in 2025, or approximately USD 460.5 million. Integrated delivery networks and academic medical centers are positioned to retain testing when rapid result availability, pathology integration, MRI access, or multidisciplinary case management matter more than the lowest unit cost.

Physician practice-owned central laboratories generated USD 427.1 million in 2025. Their commercial case depends on shortening the interval between testing and a urology consultation or biopsy decision. Compact immunoassay systems, reflex testing, and point-of-care formats may be attractive in this setting, but adoption is constrained by capital requirements, quality oversight, and test reimbursement.

Other end users represented the remaining market share and include public health, Veterans Affairs, and community-based care settings. These channels are relevant to access expansion, particularly where a centralized reference-laboratory model is required to serve rural or resource-constrained practices.

Channel economics reinforce that split. National reference laboratories are suited to standardized, high-throughput PSA processing and centralized specialty testing, while hospital and physician-practice laboratories compete on workflow integration and turnaround. Physician-owned laboratories have the strongest incentive to adopt reflex testing when it can be embedded in a same-visit urology workflow, but they face the greatest exposure to reimbursement complexity and platform investment requirements.

U.S. Prostate-Specific Antigen Test Market Regional Analysis

South

The South provides a substantial volume base for PSA testing because of its large older male population, including major Medicare markets in states such as Florida and Texas. Elevated disease burden among Black men also makes targeted screening access particularly important across parts of the region. . The commercial opportunity is concentrated in scalable routine testing, physician outreach, and referral pathways that improve follow-up after an elevated result.

Northeast

The Northeast has dense academic medical center, cancer-center, and specialist-laboratory infrastructure. These settings are more capable of integrating prostate MRI, biopsy navigation, tissue genomics, and multidisciplinary treatment planning. Their concentration supports earlier uptake of premium confirmatory assays, particularly where private insurance coverage and specialist referral networks facilitate adoption.

Midwest

The Midwest combines large integrated health systems with important diagnostics operations and academic referral centers. This creates a mixed market: high-throughput routine PSA testing is supported by consolidated laboratory networks, while specialized prostate cancer centers provide demand for advanced biomarkers, imaging, and genomic classifiers.

West

The West is an important innovation market for advanced prostate cancer management, supported by specialist urology practices, academic medical centers, and imaging infrastructure. Philips reports that its prostate cancer imaging solution is deployed at 22 of the 25 top U.S. cancer hospitals, illustrating how high-end imaging systems are concentrated in leading specialist settings. The region's commercial opportunity is therefore weighted toward MRI-enabled diagnostic pathways and testing that supports active-surveillance and treatment-selection decisions.

Across all regions, rural access remains a limiting factor. Lower specialist density, transportation barriers, and reduced local laboratory capacity can delay the transition from a PSA result to confirmatory workup. Centralized reference testing and digitally enabled referral pathways can mitigate some friction, but they do not fully replace local access to urology, MRI, and biopsy services.

This divergence matters for suppliers. Immunoassay manufacturers and reference laboratories benefit from broad contracts and dependable specimen logistics, whereas advanced-test developers need focused account coverage across urology groups, cancer centers, pathology departments, and MRI-enabled sites. Geographic strategy should therefore follow the site of clinical decision-making, not only population size.

U.S. Prostate-Specific Antigen Test Market Share & Competitive Landscape

Competition is organized around distinct diagnostic roles rather than a single product category. Routine immunoassay suppliers compete on installed base, throughput, assay standardization, and laboratory connectivity. Specialist biomarker and genomic companies compete on clinical evidence, payer coverage, and their ability to influence biopsy or treatment decisions. Imaging providers and laboratory operators link these layers into usable clinical workflows.

Abbott Laboratories participates through its immunoassay footprint and, following its March 2026 acquisition of Exact Sciences, through broader oncology diagnostics capabilities. The transaction increases Abbott's potential to connect routine laboratory access with downstream cancer-risk tools.

Advacare Pharma and CTK Biotech, Inc. (SSI Diagnostica Group) address rapid-test and decentralized testing formats. Their positioning is most relevant where an office or community setting values simple PSA assessment without a large automated analyzer.

Cleveland Diagnostics, Inc. is differentiated by IsoPSA, which received FDA approval in December 2025 as a biopsy decision-support test for eligible patients with elevated PSA. . Its commercial challenge is converting regulatory and guideline visibility into sustained payer and laboratory adoption.

Danaher Corporation, primarily through Beckman Coulter Diagnostics, competes with Access immunoassay platforms and the PHI multi-marker test. Its integrated assay-and-algorithm offering is relevant to laboratories seeking to retain PSA reflex testing rather than refer all specialty work externally.

F. Hoffmann-La Roche Ltd. competes in high-throughput laboratory testing through Elecsys total PSA and free PSA assays on cobas e systems. Its position depends on large-account laboratory relationships and broad routine immunoassay menu coverage.

GE HealthCare Technologies Inc. Koelis SAS, and Koninklijke Philips N.V. participate in the confirmatory imaging and biopsy-guidance layer. GE HealthCare supports MRI-based prostate assessment workflows, while Philips offers MRI analysis and fusion-biopsy capabilities through DynaCAD Prostate and UroNav,. Koelis competes through image-fusion and biopsy-navigation technology.

Glycanostics, s.r.o. represents an emerging differentiation approach based on PSA glycoform analysis. Published research on cancer-associated glycan-carrying PSA demonstrates the potential for enhanced discrimination versus total PSA, although broader clinical validation and commercialization remain necessary.

LabCorp Holdings Inc. and Quest Diagnostics are major processing and distribution channels for routine PSA testing and selected specialty diagnostics. Quest's national infrastructure also gives emerging assay developers a route to broad provider access without building a full laboratory network independently.

MDxHealth SA has assembled a prostate-focused portfolio spanning urine-based, tissue-based, and genomic testing. Its September 2025 acquisition of Exosome Diagnostics strengthened that strategy by adding ExoDx Prostate and laboratory assets.

Myriad Genetics, Inc. competes in tissue-based genomic risk stratification through Prolaris, with a focus on treatment-selection and active-surveillance decisions. OPKO Health, Inc. differentiates through 4Kscore and BioReference laboratory operations, linking a multi-kallikrein risk model with a specialty testing channel,.

Siemens Healthineers AG maintains broad PSA assay availability across multiple immunoassay platforms, including Atellica IM, ADVIA Centaur, Dimension Vista, and IMMULITE systems. Its December 2025 tPSAII approval supports continued migration toward newer automated testing architecture.

Veracyte, Inc. is positioned in the genomic classifier segment through Decipher Prostate, supported by its reported NCCN Advanced Tools recognition. The company's advantage depends on demonstrating that genomic information changes a decision with sufficient clinical and economic value to support coverage.

Recent Industry Developments

• In March 2026, Abbott completed its acquisition of Exact Sciences on March 23, 2026, expanding its cancer diagnostics portfolio and adding Exact Sciences' oncology testing assets. The transaction may strengthen Abbott's ability to participate in diagnostic pathways extending from routine laboratory testing to downstream cancer-risk stratification.
• In December 2025, The FDA approved IsoPSA under PMA P200048, with a decision date of November 28, 2025. Cleveland Diagnostics announced FDA approval on December 1, 2025, positioning the assay as a blood-based aid in biopsy decision-making for men aged 50 years and older with elevated PSA.
• In December 2025, The FDA approved Siemens Healthineers' Atellica IM Total PSA II under PMA P240021 on December 3, 2025. The assay is a quantitative automated immunoassay standardized against the WHO 17/100 reference preparation.